StreetInsider.com News Articles

H.C. Wainwright Downgrades Caribou Biosciences Inc. (CRBU) to Neutral, 'Operations Halted'

Thu, 08 Oct 2026 06:16:46 -0400

(Updated - October 8, 2026 6:16 AM EDT)

H.C. Wainwright analyst Robert Burns downgraded Caribou Biosciences Inc. (NASDAQ: CRBU) from Buy to Neutral.

The analyst comments "Strategic alternatives being explored as all clinical programs are halted. Earlier this week, Caribou announced that it is exploring strategic alternatives to maximize stockholder value and plans to discontinue further development activities for its two allogeneic CART cell therapy programs, vispa-cel for the treatment of relapsed or refractory (r/r) B cell non-Hodgkin lymphoma and CB-011 for the treatment of r/r multiple myeloma. In line with this decision, Caribou will implement workforce and cost reductions, which are

H.C. Wainwright Downgrades Caribou Biosciences Inc. (CRBU) to Neutral, 'Operations Halted'

Thu, 08 Oct 2026 06:16:46 -0400

(Updated - October 8, 2026 6:16 AM EDT)

H.C. Wainwright analyst Robert Burns downgraded Caribou Biosciences Inc. (NASDAQ: CRBU) from Buy to Neutral.

Brookline Capital Markets Downgrades Caribou Biosciences Inc. (CRBU) to Hold

Wed, 07 Oct 2026 04:34:09 -0400

Brookline Capital Markets analyst Leah Cann downgraded Caribou Biosciences Inc. (NASDAQ: CRBU) from Buy to Hold.

For an analyst ratings summary and ratings history on Caribou Biosciences Inc. click here. For more ratings news on Caribou Biosciences Inc. click here.

Shares of Caribou Biosciences Inc. closed at $1.14 yesterday.

RBC Capital Downgrades Caribou Biosciences Inc. (CRBU) to Sector Perform

Wed, 07 Oct 2026 02:34:00 -0400

RBC Capital analyst Luca Issi downgraded Caribou Biosciences Inc. (NASDAQ: CRBU) from Outperform to Sector Perform with a price target of $1.00 (from $10.00).

The analyst comments: “CRBU announced it is exploring strategic alternatives and plans to discontinue further development of both of its allogeneic CAR-T programs vispa-cel (anti-CD19 for LBCL) and CB-011 (anti-BCMA, r/r MM). The company cited challenging financing environment for allogeneic CAR-T cell therapies and lack of capital availability as reasons for today's decision, and plans to complete most of the clinical discontinuation and workforce reduction in 4Q26. Downgrade to Sector Perform; PT to $1 from $10.”

For an

RBC Capital Downgrades Caribou Biosciences Inc. (CRBU) to Sector Perform

Wed, 07 Oct 2026 02:34:00 -0400

RBC Capital analyst Luca Issi downgraded Caribou Biosciences Inc. (NASDAQ: CRBU) from Outperform to Sector Perform with a price target of $1.00 (from $10.00).

For an

Leerink Downgrades Caribou Biosciences Inc. (CRBU) to Market Perform

Wed, 07 Oct 2026 02:32:25 -0400

Leerink analyst Daina Graybosch downgraded Caribou Biosciences Inc. (NASDAQ: CRBU) from Outperform to Market Perform with a price target of $1.00 (from $4.00).

The analyst comments: “Caribou announced that the company is exploring strategic alternatives to maximize stockholder value in a press release (PR). As part of the initiative, the company is discontinuing the development of both of their gene-edited allogeneic, or off-the-shelf CAR-T cell therapies for hematologic malignancies: vispa-cel for relapsed or refractory (r/r) B-cell lymphomas; and CB-011 for r/r multiple myeloma (RRMM). Caribou will implement a workforce and cost-reduction initiative as part of the evaluation process.

We are sympathetic to

Leerink Downgrades Caribou Biosciences Inc. (CRBU) to Market Perform

Wed, 07 Oct 2026 02:32:25 -0400

Leerink analyst Daina Graybosch downgraded Caribou Biosciences Inc. (NASDAQ: CRBU) from Outperform to Market Perform with a price target of $1.00 (from $4.00).

We are sympathetic to

Form 8-K Caribou Biosciences, For: Oct 02

Tue, 06 Oct 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20261006/27155520.html

Caribou Biosciences to halt CAR-T programs, explore sale

Tue, 06 Oct 2026 16:05:58 -0400

Caribou Biosciences, Inc. (Nasdaq: CRBU) announced it is exploring strategic alternatives, including a potential merger, acquisition, or business combination, and plans to discontinue its two allogeneic CAR-T cell therapy programs.

The Berkeley, California-based company said its board of directors approved initiating the review process and has engaged Wedbush Securities Inc. as its exclusive financial advisor. Caribou said it has not set a timeline for completing the review and does not intend to provide updates unless a course of action is approved or other disclosure is required.